Skip to main content
NUWE logo

NUWE · Nuwellis, Inc.

Track NUWE — free
$3.50 -0.31 (-8.14%)
Market Cap
$2.06M
Shares
540,912
Volume · Nov 20 4561 Avg daily vol (18 sessions) 2.34M

Price & Indicators

 

Key stats

Close
$3.81
Thu 19 Nov
Open
$3.90
Thu 19 Nov
Average volume, 30 days
1.5M
shares a session
Short interest
196K
36.2% of shares · 1.0 days to cover
Day range
$3.75$4.10
Open $3.90 Close $3.81
52-week closing range
$0.32$146.65
Close $3.81 97.4% under the high
Short volume, last session
11%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 12
Price history
Oct 2020 to Nov 2026

Up next

Mar 9, 2027 Est · unconfirmed · in 16 wks

Latest documents

2026
Nov 17
Current report 8-K
Year-to-Date Revenue Up 13%, Gross Margin Rises to 72%

Nuwellis posted an updated investor presentation on November 17, 2026, reporting 13% year-to-date revenue growth, gross margin of 72% versus 59% a year earlier, and cash runway through Q2 2027.

Regulation FD disclosure
4 source passages
On November 17, 2026, Nuwellis, Inc. (the “Company”) posted an updated corporate presentation to its website YTD revenue growth of 13% over the prior-year period YTD gross margins improved to 72% compared to 59% in the prior-year period Cash runway through Q2 2027 supports execution of near-term growth initiatives Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash reaches $8.4 million after $6.7 million financing

Nuwellis raised approximately $6.7 million through a registered direct offering and concurrent Series C warrant exercises. Cash, cash equivalents and restricted cash totaled $8.4 million as of September 30, 2026, supporting operations through the second quarter of 2027.

Read from the MD&A section
4 source passages
Closed a registered direct offering on August 3, 2026, raising approximately $3.4 million in gross proceeds, and received approximately $3.3 million in gross proceeds from the concurrent exercise of Series C Warrants for aggregate proceeds of approximately $6.7 million. As of September 30, 2026, and December 31, 2025, cash, cash equivalents, and restricted cash were $8.4 million and $1.2 million, respectively. We believe our existing capital resources will support operations through the second quarter of 2027, but we will require additional capital to fund operations through the end of fiscal year 2027. Nuwellis is dedicated to advancing cardiorenal care by enabling earlier, safer, and more controlled fluid management for patients. Open the document at this passage
Nov 12
Current report 8-K
Gross margin expansion and cost cuts narrowed operating loss

Nuwellis reported third-quarter net sales of $2.2 million, operating loss improved 24% to $2.1 million, gross margin expanded to 69.5%, and cash and cash equivalents reached $8.3 million as of September 30, 2026.

Financial results
5 source passages
MINNEAPOLIS – November 12, 2026 – Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and nine months ended September 30, 2026. Operating loss for the third quarter of 2026 improved 24% year over year to $2.1 million, driven by 430 basis points of gross margin expansion and a 13% reduction in operating expenses, primarily reflecting outsourced manufacturing efficiencies and efforts to align expenses with the highest-priority commercial and strategic programs. Net sales were $2.2 million in the third quarter of 2026, essentially unchanged versus the prior-year quarter, as the prior-year period benefited from fulfilling $0.4 million in accumulated backorders. Third-quarter 2026 gross margin expanded to 69.5% from 65.2% in the prior-year quarter, reflecting higher average selling prices and continued benefits from the Company's contract manufacturing model. Year-to-date gross margin improved to 71.7%, compared with 59.4% in the prior-year period. Strengthened the Company's balance sheet as of September 30, 2026, with $8.3 million in cash and cash equivalents. Open the document at this passage
Oct 23
Current report 8-K Events of Oct 22
Nuwellis Sets One-for-Nine Reverse Stock Split Effective October 26

Nuwellis approved a one-for-nine reverse stock split of its common stock, effective at 5:00 p.m. Eastern Time on October 26, 2026. Shares will trade split-adjusted on the Nasdaq Capital Market under NUWE starting October 27, 2026.

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change
2 source passages
the Board approved a one-for-nine reverse stock split of the Company’s issued and outstanding shares of common stock The Reverse Stock Split will become effective as of 5:00 p.m. Eastern Time on October 26, 2026, and the Company’s common stock will begin trading on a split-adjusted basis when the market opens on October 27, 2026. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$9.01M
Trailing 12 months
Net income (TTM)
−$13.76M
Trailing 12 months
Revenue growth YoY
-0.2%
Year over year
Operating margin
-135.8%
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 504,205.5%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+12,688.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
36.2%
Latest settlement · 1.0 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26

TL;DR. Nuwellis (NUWE) reported Q2 2026 revenue of $2.0 million, up 14% year-over-year with U.S. revenue up 17%, while gross margin expanded to 76% from 56% and the installed base grew with 24 consoles sold in the first half versus 5 a year earlier; the company also raised approximately $12.7 million in gross proceeds, appointed a new CEO, and advanced the proposed Aquadex pediatric label expansion following an FDA pre-submission meeting.

Bullish
  • + Q2 revenue grew 14% YoY to $1.97 million, with U.S. revenue up 17% and H1 revenue up 20%
  • + Gross margin expanded to 76% from 56% on pricing, mix, and contract manufacturing
  • + Installed base grew sharply, with 24 consoles sold in H1 versus 5 in H1 2025
  • + Raised approximately $12.7 million in gross proceeds, including $6.0 million in June and ~$6.7 million post-quarter
  • + Pediatric footprint expanded into two new states (Michigan and Wisconsin) plus additional South Carolina system
Bearish
  • − Q2 net loss was $4.8 million, though narrower than the $12.6 million prior-year loss
  • − Operating expenses rose to $4.7 million in Q2 from $3.9 million a year ago

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −81%
below
Price vs 50-day avg +69%
above
RSI (14) 51
neutral
MACD trend Negative
52-week position 2%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +633%
trailing
6-month return −86%
trailing
YTD return −94%
this year
Relative strength −80%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $20 — 200d above 50d
Institutional flow Accumulating
+120% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
36.16% of shares out · ▲ +1869.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
11 holders — mid 3-yr range
Squeeze score 79
high risk · 0–100
Fundamentals
Fair
Revenue growth −5%
Y/Y
Gross margin 62%
contracting
EPS growth +93%
Y/Y
Free cash flow $-10.9M
Quant / Vol
risk profile
Very High
Volatility 1610%
annualized · 1-yr
Max drawdown −100%
past year
ATR 14.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−81% Bearish
Price vs 50-day avg
+69% Bullish
RSI (14)
51 Neutral
MACD trend
Negative Bearish
52-week position
2% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $20 — 200d above 50d
Institutional flow Accumulating
+120% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
36.16% of shares out · ▲ +1869.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
11 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $4 · 2% Range high $147
vs 200-day avg -81% vs 50-day avg +69%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Aquadex consoles sold 32 first nine months of 2026 —
Gross margin 71.7% year-to-date 2026 (nine months ended September 30, 2026) —
Shares sold under ATM 134,488 the three months ended September 30, 2026 filing —
consoles sold 24 first half of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NUWE
Nuwellis, Inc.
this stock
$2.06M — -5.4% — 36.2%
ABT
Abbott Laboratories
$179.90B -17.1% +5.7% 38.8 1.1%
MDT
Medtronic plc
$128.69B +4.7% +8.4% 24.8 1.8%
SYK
Stryker Corp
$119.19B -10.9% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
$62.31B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
11
% held
6.0%
Net QoQ
+30.1K sh
Top holder
JANE STREET GROUP, LLC
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Rising
Shares short
195.6K
Days to cover
1.0d
Change
+185.7K sh
View
Short Volume
Short vol %
11%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
73.3K
Value
$423.8K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
61.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$8.3M
Net income (FY)
$-17.5M
EPS diluted
$-7997.85
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 17, 2026
This year
34

Nuwellis posted an updated investor presentation on November 17, 2026, reporting 13% year-to-date revenue growth, gross margin of 72% versus 59% a year earlier, and cash runway through Q2 2027.

View
Exempt Offerings
Offering
$3.8M
Filed
Nov 20, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Nuwellis Reports Third Quarter 20…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
NUWE -24.3% +632.7% -85.9% -32.9% -93.7%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -18.8% +639.0% -80.2% -27.7% -98.7%
Key facts CIK 1506492 CUSIP 67113Y884 13F (30d) 15 filings 12 filers Visit website Investor relations